Samuel Bates Martin
CIK: 0001709024
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Celldex Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 25, 2026CLDX
Celldex Therapeutics, Inc.
Award(A)DirectIncentive Stock Option (right to buy)
93K shares- - Jan 2, 2026CLDX
Celldex Therapeutics, Inc.
Exercise(M)Direct4.8K shares at avg. $10.38$50K - Jun 5, 2025CLDX
Celldex Therapeutics, Inc.
Award(A)DirectIncentive Stock Option (right to buy)
81K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | Award(A) Incentive Stock Option (right to buy) | 93,000 | - | - | Direct |
| Jan 2, 2026 | CLDX Celldex Therapeutics, Inc. | Exercise(M) | 4,817 | $10.38 | $50,000 | Direct |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | Award(A) Incentive Stock Option (right to buy) | 81,000 | - | - | Direct |
1-3 of 3 transactions
About Martin Samuel Bates
Martin Samuel Bates (SEC CIK 0001709024) files insider reports with the SEC as SVP AND CFO of Celldex Therapeutics, Inc. (CLDX).
Signal8 holds 3 ownership filings by Martin Samuel Bates, all Form 4s, filed between Jun 9, 2025 and Jun 29, 2026. Those filings report 3 transactions, from Jun 5, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Martin Samuel Bates's filings is in HAMPTON, NJ.
Recent filings by Martin Samuel Bates
Other insiders filing for Celldex Therapeutics, Inc. (CLDX)
- Lawver Teri L, SVP & Chief Commercial Officer
- Jimenez Freddy A., SVP & GENERAL COUNSEL
- Young Diane C., SVP, CHIEF MEDICAL OFFICER
- Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS
- Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN.
- Crowley Elizabeth, SR. VP & CPDO